4 December 2024
Latham & Watkins Advises on Core Scientific’s Upsized US$550 Million Convertible Senior Notes Offering
Advising firms
Deal team
9 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Greg Rodgers Lead | Latham & Watkins LLP | Partner | capital markets | Not stated |
| Andrew Blumenthal Lead | Latham & Watkins LLP | Partner | capital markets | Not stated |
| Ryan Gold | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Andrew Bentz | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Adam Weber | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Karysa Norris | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Dylan Shamoon | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Aaron Bernstein | Latham & Watkins LLP | Partner | tax | Not stated |
| James Aldred | Latham & Watkins LLP | Associate | tax | Not stated |
Stated terms
- Stated value
- USD 550m (US$550 million)
- What the figure measures
- Issue size
- Client
- Core Scientific, Inc.Issuer
- Counterparties
- initial purchasers (Underwriters)